Enzo Biochem Stock

Enzo Biochem Equity

Delisted·Apr 17, 2025

The The Equity of Enzo Biochem (ENZ) as of Aug 1, 2026 is 56.11 M USD. In the previous year, The Equity was 78.46 M USD — a change of -28.49% (lower).

Equity

56.11 MUSD

YoY

-28.49%

Last updated:

In 2026, Enzo Biochem's equity was 56.11 M USD, a -28.49% increase from the 78.46 M USD equity in the previous year.

Access this data via the Eulerpool API

Enzo Biochem Stock analysis

What does Enzo Biochem do? Enzo Biochem Inc is a US-based company operating in the biotechnology sector. It was founded in 1976 by Elazar Rabbani and is headquartered in New York. The company focuses on developing, producing, and marketing innovative diagnostic and therapeutic products for the medical industry. Enzo Biochem Inc's business model is based on the application of modern technologies for the development and synthesis of molecules for medical technology and life sciences. At the same time, the company also offers diagnostic testing systems and clinical laboratory services to its customers. Enzo Biochem's business model is therefore diverse and covers various areas. Enzo Biochem divides its business into three main segments: life sciences, clinical labs, and therapeutics. In the life sciences segment, the company engages in research and development of technologies for synthesizing molecules for medical technology. In the clinical labs segment, Enzo Biochem offers diagnostic testing systems and clinical laboratory services for use in medical diagnostics. The therapeutics segment manufactures therapeutic products for the treatment of viral infections. Enzo Biochem's product offering includes a wide range of products and services. This includes molecules for medical technology, diagnostic testing systems, and therapy products for viral infections. The product lines of Enzo Biochem include: - Molecules for medical technology: Enzo Biochem has developed a wide range of molecules for medical technology and is a leader in this field. These molecules include proteins, antibodies, and other biomolecules. The company also offers custom molecules for specific applications. - Diagnostic testing systems: The company offers a wide range of diagnostic testing systems tailored to the needs of laboratories and clinics. The tests include tests for infectious diseases, cancer, metabolic disorders, and other diseases. - Clinical laboratory services: Enzo Biochem provides a wide range of clinical laboratory services, including blood tests, microbiological tests, urine, stool, and body fluid tests, as well as histological analysis of tissue samples. - Therapy products: Enzo Biochem has developed a broad portfolio of therapy products for the treatment of viral infections. These products include immunomodulators, antivirals, and other therapeutics aimed at combating various pathogens. Enzo Biochem has made a name for itself in the biotechnology industry through continuous innovation and high-quality products. The company has also engaged in partnerships, acquisitions, and joint ventures to expand its global footprint. It has a global presence and works with leading pharmaceutical and biotech companies from around the world. Overall, Enzo Biochem has established itself as a leading biotechnology company operating in the fields of life sciences, clinical labs, and therapeutics. The company offers a wide range of products and services tailored to the needs of laboratories and clinics. Enzo Biochem has established itself as an innovation leader in the biotechnology industry and is committed to further expanding its business through the development of new products and technologies. Enzo Biochem is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Enzo Biochem's Equity

Enzo Biochem's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Enzo Biochem's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Enzo Biochem's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Enzo Biochem's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Enzo Biochem’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Enzo Biochem stock

The Equity of Enzo Biochem is 56.11 M USD in 2026.

Access this data via the Eulerpool API

Balance Sheet — Enzo Biochem

All Key Metrics — Enzo Biochem